A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
Completed · Phase 1 · NCT06970301
Conditions: Healthy Study Participants
At a glance
- Research payments reported, 2025
- $7,921
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 32
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- glovadalen (drug), Placebo (other)
- Dates
- Started 2025-04-28; completion 2026-05-29
- Results posted
- Not yet
The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.
From ClinicalTrials.gov, last updated 2026-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $7,921 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.